20 results about "Acute cerebral infarction" patented technology

The invention relates to the technical field of disease analysis, and provides an acute-stage cerebral infarction detection system and method.The method comprises the steps that basic information, physical sign data and blood sample data of a brain patient are collected, and data integration is conducted to obtain integrated data; a brain scanning image is obtained, and a high-definition brain image is obtained after artifacts are removed; recognizing image semantics, performing image segmentation, evaluating a segmentation level, and obtaining a target image when a preset level is met; identifying brain lesion features by using the target image; an angiogram is collected, the brain blood vessel caliber is calculated, and the brain blood perfusion condition is analyzed; constructing a blood vessel network by using the angiogram, and analyzing a blood vessel variation degree; based on the blood vessel caliber, the blood perfusion condition and the blood vessel variation degree, analyzing the brain blood vessel lesion degree; collecting an electroencephalogram, and analyzing brain activity characteristics; and performing acute-stage cerebral infarction analysis based on the integrated data, the brain lesion features, the brain vascular lesion degree and the brain activity features. The invention aims to improve the rationality of acute cerebral infarction detection.

The present invention discloses the use of an inhibitor anti-CD90.2, which can reduce the expression of innate lymphoid cells and thus can be used as an anti-pneumonia preparation targeting ILC for post-infarct pneumonia. The expression of ILC2 cells in patients with acute cerebral infarction increases. After the clearance of ILC, differential expression of pneumonia-related indicators is observed in patients with acute cerebral infarction, indicating that ILC2 promotes pneumonia after cerebral infarction. The inhibitor anti-CD90.2 (250 μg / mouse) was injected into Rag- / - mice 48 hours before modeling. The expression of ILC2 was measured 24 hours after MCAO modeling and was found to decrease, indicating that the inhibitor anti-CD90.2 can play an anti-pneumonia role by reducing the expression of ILC2 in mice with acute cerebral infarction. The present invention provides a new target for the prevention and treatment of pneumonia, a complication after acute cerebral infarction surgery. At the same time, it is proposed that the inhibitor anti-CD90.2 reduces the expression of ILC2 and thus can be used as an anti-pneumonia preparation targeting ILC2, achieving an effective combination of theoretical research and practical application.

The present disclosure includes a communication unit that communicates with an imaging device that captures images of patients with acute cerebral infarction, and a processor that controls operations related to predicting the time of occurrence of acute cerebral infarction, wherein the processor receives images of patients with acute cerebral infarction from the imaging device via the communication unit, classifies the images into a first image corresponding to a water-suppressed image and a second image corresponding to a diffusion-weighted image, acquires the first image and the second image, aligns the first image and the second image with an MNI area corresponding to an activated area of ​​the brain, detects an infarct area in the second image, and outputs a probability prediction value for the time of occurrence of acute cerebral infarction based on the first image, the second image, and the infarct area.

The invention discloses a micro-catheter control method for an acute cerebral infarction interventional thrombectomy, which comprises the following steps: a micro-catheter control system acquires current position state information of a micro-catheter, and drives the micro-catheter to move to a target position according to preset parameters; three-dimensional position coordinates of the microcatheter are obtained in real time through an information acquisition module; the signal processing unit compares the actual position of the microcatheter with a preset target position in real time, judges whether the microcatheter reaches the preset position or not, and receives manually input adjustment parameters when it is monitored that the resistance exceeds a threshold value or the position deviates from a path; and the signal processing unit regenerates a control instruction based on the updated parameters, and drives the microcatheter to continuously move according to the corrected parameter constraint. By acquiring the illness state and blood vessel anatomical structure information of a patient, setting the parameters such as the target position and the moving path of the microcatheter and combining the three-dimensional position coordinate information acquired by the position sensor, the microcatheter can be accurately controlled to reach the target position and move according to the preset path.

The present disclosure may include a communication module configured to perform communication with an imaging device that captures an image of an acute cerebral infarction patient; and a processor configured to receive the image of the acute cerebral infarction patient from the imaging device through the communication module, classify the image into a first image corresponding to a liquid attenuation inversion recovery image and a second image corresponding to a diffusion-weighted image, acquire the first image and the second image, align the first image and the second image with respect to an MNI region corresponding to an activated region of a brain, detect an infarction region in the second image, and output a probability prediction value for the occurrence time of acute cerebral infarction based on the first image, the second image, and the infarction region.

The present invention relates to recombinant batroxobin and a method for its preparation on an industrial scale with high expression level. Specifically, the method for preparing recombinant batroxobin according to the present invention is to artificially synthesize the structural gene sequence of batroxobin, then use Pichia pastoris to clone and express to screen and obtain the seed liquid of a high-expression engineering strain, and then ferment and culture to prepare recombinant batroxobin according to the following operations: preparation of primary seed liquid, preparation of secondary seed liquid, inoculation and pre-culture in a fermenter, glycerol fed-batch culture, methanol fed-batch induction culture, concentration to obtain a fermentation concentrate containing recombinant batroxobin and optionally purifying it. This recombinant batroxobin can be clinically used for acute cerebral infarction, for improving ischemic symptoms caused by various occlusive vascular diseases (such as thromboangiitis obliterans, deep phlebitis, pulmonary embolism, etc.), and for improving peripheral and microcirculation disorders (such as sudden deafness, motion sickness). The expression level of batroxobin by the method of the present invention is high, and industrial-scale production can be easily achieved.

The present application relates to a kit for predicting whether a subject has a cardiovascular disease, particularly a cardiovascular event, and to the use of a reagent for determining the level of a biomarker in a biological sample in the preparation of the kit. The biomarker of the present application can be used to predict the risk of cardiovascular disease, particularly cardiovascular events (such as acute myocardial infarction, acute heart failure, acute cerebral infarction, and sudden death) in a subject (such as a subject with diabetes).

The present invention relates to the technical field of cell therapy. Specifically disclosed are a mesenchymal stromal cell-based drug and a use thereof in the treatment of acute cerebral infarction. The present invention provides a cell-based drug, comprising mesenchymal stromal cells and a pharmaceutically acceptable excipient. Compared with stem cells, the mesenchymal stromal cells have a negative expression level of mRNA encoding self-renewal and differentiation in the mesenchymal stromal cells. The mesenchymal stromal cells account for 90% or more of the cell-based drug. The cell-based drug exhibits the characteristics and mechanism of action of stromal cells, homes to the neovasculature formed by endothelial cells at the injury site within an effective time window, plays a role in promoting / maintaining the neovasculature and remodeling the microenvironment of the injury site, fully ensures the safety and effectiveness of disease treatment, and provides a novel method for the diagnosis and treatment of related diseases.

This invention belongs to the field of medical device technology, specifically a carotid artery bypass catheter with a distal embolization protector. Addressing the problems of high risk of cerebral infarction due to plaque detachment during existing carotid endarterectomy procedures, as well as the cumbersome nature of current composite surgical procedures and reliance on specialized operating room conditions, this invention proposes the following solution: It includes a bypass catheter body and a distal embolization protection mechanism, connected together; it also includes a proximal end and a distal end. By integrating blood bypass and distal embolization protection functions into one unit, this invention allows surgeons to perform the procedure independently in a regular operating room without relying on a composite operating room. While establishing intraoperative blood bypass, it effectively intercepts potentially detached plaques or thrombi, significantly reducing the risk of postoperative acute cerebral infarction, decreasing disability and mortality rates, and simplifying the surgical procedure while shortening anesthesia and surgical time.

The application discloses a kind of acute cerebral infarction thrombolysis hemorrhage patient treatment combined cold deposit intervention device, it is related to cold deposit infusion technical field, including base, cross transfer box is rotatably connected on base;It also includes infusion hard pipe, infusion hose, fixed plate, first spring, limit frame, drive assembly and fixing mechanism, the end of infusion hose with needle is placed on placement table, infusion hard pipe lower portion is connected with fixed plate, first spring is connected between fixed plate and support, first spring is wound on infusion hard pipe, infusion hard pipe upper portion is connected with limit frame, cross transfer box lower portion is provided with drive assembly, cross transfer box is equipped with the fixing mechanism for clamping and fixing blood bag.The application is first by fixed mechanism to blood bag clamping and fixing, then by drive assembly, realize blood bag automatic replacement, avoid when infusion medical staff cannot leave sickbed, cause medical staff waste, improve the operation convenience of device.

The invention discloses a prediction system for the therapeutic effect of Chinese medicine prescriptions for acute cerebral infarction based on machine learning, including: an acquisition module, which acquires the Chinese medicine prescriptions for acute cerebral infarction to be predicted; a model generation module, which takes each Chinese medicine in the Chinese medicine prescriptions for acute cerebral infarction to be predicted as a node, establishes undirected edges between all the Chinese medicines contained in the current prescription, and generates a complex network model; a proximity calculation module, which calculates the relative proximity of each node based on the complex network model; a feature selection module, which sorts the relative proximity of all nodes in the Chinese medicine prescriptions for acute cerebral infarction to be predicted in descending order, and selects several relative proximity degrees with the highest sorting as the features of the current Chinese medicine prescription sample; a prediction module, which obtains the prediction result of the therapeutic effect of the Chinese medicine prescription based on the features of the current Chinese medicine prescription sample and the trained machine learning model. Through the trained random forest model, the drug efficacy prediction of acute cerebral infarction disease is realized.

The invention discloses a uterus-calming bezoar pill which is prepared from the following raw material components in parts by weight: 80 to 120 parts of bezoar, 150 to 250 parts of buffalo horn concentrated powder, 20 to 30 parts of artificial musk, 40 to 60 parts of pearl, 80 to 120 parts of cinnabar, 80 to 120 parts of realgar, 80 to 120 parts of coptis chinensis, 80 to 120 parts of scutellaria baicalensis, 80 to 120 parts of gardenia, 80 to 120 parts of curcuma aromatica, 20 to 30 parts of borneol, 80 to 120 parts of ligusticum wallichii, 60 to 100 parts of safflower, 80 to 120 parts of gastrodia elata and 60 to 100 parts of fructus viticis. The traditional Chinese medicines for promoting blood circulation to remove blood stasis and guiding medicines to move upwards are added on the basis of an original prescription, and the obvious effect on treating acute cerebral infarction caused by phlegm-heat internal closure is achieved by clearing away heat and toxic materials, eliminating phlegm and inducing resuscitation, promoting blood circulation to remove blood stasis, guiding medicines to move upwards and calming the nerves.

This invention belongs to the field of medical data processing technology, specifically a method for constructing an intelligent prediction model for symptomatic hemorrhage transformation in acute ischemic stroke. The method includes step one: data acquisition and preprocessing: collecting clinical and imaging data of patients with acute ischemic stroke; the clinical data includes gender and the time from onset to intravenous thrombolysis; the imaging data includes the relative apparent diffusion coefficient value. This method for constructing an intelligent prediction model for symptomatic hemorrhage transformation in acute ischemic stroke, through setting a prediction model construction method, provides high visualization of the prediction of symptomatic hemorrhage transformation in acute ischemic stroke, and is convenient for clinical application. It utilizes a large language model to generate an interactive web interface, automatically generating native HTML code based on the prediction equation. The web interface includes an input module (receiving gender, DNT, and rADC values), a calculation module (calculating the probability value P in real time based on the equation), and a visualization module (displaying the results in a graphical form); further, the graphical form is limited to a bar chart.

The present application relates to a kit for predicting whether a subject has a cardiovascular disease, particularly a cardiovascular event, and to the use of a reagent for determining the level of a biomarker in a biological sample in the preparation of the kit. The biomarker of the present application can be used to predict the risk of cardiovascular disease, particularly cardiovascular events (such as acute myocardial infarction, acute heart failure, acute cerebral infarction, and sudden death) in a subject (such as a subject with diabetes).

The present disclosure may include a communication module configured to perform communication with an imaging device that captures an image of an acute cerebral infarction patient; and a processor configured to control an operation related to prediction of the occurrence time of acute cerebral infarction, wherein the processor is configured to: receive the image of the acute cerebral infarction patient from the imaging device through the communication module, classify the image into a first image corresponding to a liquid attenuation inversion recovery image and a second image corresponding to a diffusion-weighted image, acquire the first image and the second image, align the first image and the second image with respect to an MNI region corresponding to an activated region of a brain, detect an infarction region in the second image, and output a probability prediction value for the occurrence time of acute cerebral infarction based on the first image, the second image, and the infarction region.

The application belongs to the technical field of medicine, and particularly relates to application of trifluperidol in treatment of cerebrovascular diseases. Trifluperidol is a D1 / D2 dopamine receptor antagonist with oral activity and a novel PI3K inhibitor, and trifluperidol has anti-proliferative activity on cancer cells and induces apoptosis. The application discloses trifluperidol for the first time, and no report is found on effective treatment of trifluperidol against ischemic stroke, especially the application creatively proposes that trifluperidol significantly reduces the volume of acute cerebral infarction of a mouse with focal cerebral ischemia, which indicates that trifluperidol can be used for treating ischemic stroke.

The present application relates to a kit for predicting whether a subject has a cardiovascular disease, particularly a cardiovascular event, and to the use of a reagent for determining the level of a biomarker in a biological sample in the preparation of the kit. The biomarker of the present application can be used to predict the risk of cardiovascular disease, particularly cardiovascular events (such as acute myocardial infarction, acute heart failure, acute cerebral infarction, and sudden death) in a subject (such as a subject with diabetes).

The present invention relates to mesenchymal stem cell therapy for treating acute or subacute cerebral infarction. More specifically, the present invention relates to a pharmaceutical composition for treating acute or subacute cerebral infarction, comprising mesenchymal stem cells as an active ingredient, the pharmaceutical composition being characterized by being intravenously administered to a subject three or more times at a standard single dose.

The present invention provides a method, a device, and a program for effectively determining the cause and / or treatment policy of acute phase cerebral infarction. The method for determining the cause and / or treatment policy of acute phase cerebral infarction uses, as an indicator, an acute chronic mismatch value representing the difference or ratio between a representative value representing the maximum concentration arrival time of a contrast agent and a representative value representing the average transit time of the contrast agent, both of the representative values being obtained from cerebral perfusion image data of a patient who has developed acute phase cerebral infarction.

The invention discloses a method for predicting the occurrence probability of microemboli based on DWI infarction mode data. The method comprises the following steps: firstly, acquiring multiple groups of DWI infarction index historical data; secondly, performing correlation analysis processing on the historical data of the multiple groups of DWI infarction indexes to obtain at least one clinical index related to microembolus occurrence as an independent index; screening out historical data corresponding to each independent index to form a training data set; constructing a microembolus occurrence probability prediction model by using the training data set, and generating a Nomogram graph of the microembolus occurrence probability; and finally, obtaining real-time data of the DWI infarction index, screening out real-time data corresponding to the independent index, inputting the real-time data into the micro-embolus occurrence probability prediction model, obtaining a micro-embolus occurrence probability prediction value according to model output and the Nomogram graph, and visually displaying the micro-embolus occurrence probability prediction value. Through the modeling prediction method, the occurrence probability of the microemboli of the acute cerebral infarction patient which is difficult to carry out TCD detection can be predicted.